ACP-501 demonstrated good tolerability results in patients with stable coronary disease and is going through a phase II clinical trial designed to evaluate its impact on apoB metabolism in individuals with coronary heart disease (NCT03773172) [32]. Here, APOB is linked to coronary artery disorder.